Prognostic Value of Resistance Proteins in Plasma Cells from Multiple Myeloma Patients Treated with Bortezomib-Based Regimens

While multiple myeloma (MM) treatment with proteasome inhibitors and other agents yields encouraging results, primary and secondary resistance remains an emerging problem. An important factor in such treatment resistance is the overexpression of several proteins. The present study comprehensively ev...

Descripción completa

Detalles Bibliográficos
Autores principales: Robak, Paweł, Szemraj, Janusz, Mikulski, Damian, Drozdz, Izabela, Juszczak, Karolina, Jarych, Dariusz, Misiewicz, Małgorzata, Kościelny, Kacper, Fendler, Wojciech, Robak, Tadeusz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584776/
https://www.ncbi.nlm.nih.gov/pubmed/34768548
http://dx.doi.org/10.3390/jcm10215028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584776/
https://www.ncbi.nlm.nih.gov/pubmed/34768548
http://dx.doi.org/10.3390/jcm10215028

Ejemplares similares